Cumberland Pharmaceuticals (CPIX) Net Margin (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Net Margin across 16 years of filings, most recently posting 30.75% for Q1 2026.

• Net Margin for Q1 2026 came in at 30.75%, down 4140.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15.67% (down 840.0% YoY), and the FY2025 annual result was 5.65%, up 1055.0% from the prior year.
• Net Margin came in at 30.75% for Q1 2026 at Cumberland Pharmaceuticals, down from 7.89% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 10.66% in Q1 2025 to a low of 67.38% in Q4 2023.
• The 4-year median for Net Margin is 11.2% (2024), against an average of 14.78%.
• Across the five-year window, Net Margin jumped 5210 bps in 2024 and plunged 4140 bps in 2026, its largest moves.
• Cumberland Pharmaceuticals' Net Margin stood at 67.38% in 2023, then soared by 77 bps to 15.28% in 2024, then surged by 48 bps to 7.89% in 2025, then plunged by 290 bps to 30.75% in 2026.
• The last three Net Margin figures came in at 30.75% (Q1 2026), 7.89% (Q4 2025), and 23.5% (Q3 2025), per Business Quant data.